nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0931	0.197	CbGbCtD
Pentoxifylline—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0875	0.185	CbGbCtD
Pentoxifylline—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0875	0.185	CbGbCtD
Pentoxifylline—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0791	0.167	CbGbCtD
Pentoxifylline—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0663	0.14	CbGbCtD
Pentoxifylline—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.06	0.127	CbGbCtD
Pentoxifylline—ADORA1—nerve—acquired immunodeficiency syndrome	0.00679	0.0538	CbGeAlD
Pentoxifylline—PDE5A—endothelium—acquired immunodeficiency syndrome	0.0061	0.0483	CbGeAlD
Pentoxifylline—PDE5A—blood plasma—acquired immunodeficiency syndrome	0.00542	0.0429	CbGeAlD
Pentoxifylline—NT5E—retina—acquired immunodeficiency syndrome	0.00457	0.0362	CbGeAlD
Pentoxifylline—NT5E—skin of body—acquired immunodeficiency syndrome	0.00401	0.0318	CbGeAlD
Pentoxifylline—NT5E—lymphoid tissue—acquired immunodeficiency syndrome	0.00325	0.0258	CbGeAlD
Pentoxifylline—NT5E—blood—acquired immunodeficiency syndrome	0.00306	0.0242	CbGeAlD
Pentoxifylline—PDE5A—retina—acquired immunodeficiency syndrome	0.00297	0.0235	CbGeAlD
Pentoxifylline—NT5E—bone marrow—acquired immunodeficiency syndrome	0.00296	0.0234	CbGeAlD
Pentoxifylline—NT5E—spinal cord—acquired immunodeficiency syndrome	0.00295	0.0233	CbGeAlD
Pentoxifylline—NT5E—vagina—acquired immunodeficiency syndrome	0.00283	0.0225	CbGeAlD
Pentoxifylline—NT5E—lung—acquired immunodeficiency syndrome	0.00268	0.0212	CbGeAlD
Pentoxifylline—ADORA2B—blood—acquired immunodeficiency syndrome	0.00262	0.0208	CbGeAlD
Pentoxifylline—NT5E—nervous system—acquired immunodeficiency syndrome	0.00248	0.0197	CbGeAlD
Pentoxifylline—ADORA2B—vagina—acquired immunodeficiency syndrome	0.00243	0.0192	CbGeAlD
Pentoxifylline—NT5E—central nervous system—acquired immunodeficiency syndrome	0.00239	0.0189	CbGeAlD
Pentoxifylline—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00233	0.0185	CbGeAlD
Pentoxifylline—ADORA2A—lymphoid tissue—acquired immunodeficiency syndrome	0.00232	0.0183	CbGeAlD
Pentoxifylline—ADORA2B—lung—acquired immunodeficiency syndrome	0.0023	0.0182	CbGeAlD
Pentoxifylline—ADORA2A—blood—acquired immunodeficiency syndrome	0.00218	0.0173	CbGeAlD
Pentoxifylline—ADORA2B—nervous system—acquired immunodeficiency syndrome	0.00213	0.0168	CbGeAlD
Pentoxifylline—ADORA2A—spinal cord—acquired immunodeficiency syndrome	0.0021	0.0166	CbGeAlD
Pentoxifylline—PDE5A—digestive system—acquired immunodeficiency syndrome	0.00208	0.0165	CbGeAlD
Pentoxifylline—ADORA2B—central nervous system—acquired immunodeficiency syndrome	0.00205	0.0162	CbGeAlD
Pentoxifylline—PDE4A—lung—acquired immunodeficiency syndrome	0.00205	0.0162	CbGeAlD
Pentoxifylline—PDE5A—blood—acquired immunodeficiency syndrome	0.00198	0.0157	CbGeAlD
Pentoxifylline—NT5E—brain—acquired immunodeficiency syndrome	0.0019	0.015	CbGeAlD
Pentoxifylline—PDE5A—vagina—acquired immunodeficiency syndrome	0.00184	0.0146	CbGeAlD
Pentoxifylline—NT5E—lymph node—acquired immunodeficiency syndrome	0.00183	0.0145	CbGeAlD
Pentoxifylline—ADORA1—spinal cord—acquired immunodeficiency syndrome	0.00181	0.0144	CbGeAlD
Pentoxifylline—ADORA2A—nervous system—acquired immunodeficiency syndrome	0.00177	0.014	CbGeAlD
Pentoxifylline—ADORA1—vagina—acquired immunodeficiency syndrome	0.00174	0.0138	CbGeAlD
Pentoxifylline—PDE5A—lung—acquired immunodeficiency syndrome	0.00174	0.0138	CbGeAlD
Pentoxifylline—ADORA2A—central nervous system—acquired immunodeficiency syndrome	0.0017	0.0135	CbGeAlD
Pentoxifylline—ADORA1—lung—acquired immunodeficiency syndrome	0.00165	0.0131	CbGeAlD
Pentoxifylline—ADORA2B—brain—acquired immunodeficiency syndrome	0.00163	0.0129	CbGeAlD
Pentoxifylline—PDE5A—nervous system—acquired immunodeficiency syndrome	0.00161	0.0128	CbGeAlD
Pentoxifylline—PDE5A—central nervous system—acquired immunodeficiency syndrome	0.00155	0.0123	CbGeAlD
Pentoxifylline—ADORA1—nervous system—acquired immunodeficiency syndrome	0.00153	0.0121	CbGeAlD
Pentoxifylline—PDE4B—lymphoid tissue—acquired immunodeficiency syndrome	0.00148	0.0117	CbGeAlD
Pentoxifylline—ADORA1—central nervous system—acquired immunodeficiency syndrome	0.00147	0.0117	CbGeAlD
Pentoxifylline—PDE4A—brain—acquired immunodeficiency syndrome	0.00145	0.0115	CbGeAlD
Pentoxifylline—PDE4A—lymph node—acquired immunodeficiency syndrome	0.0014	0.0111	CbGeAlD
Pentoxifylline—PDE4B—blood—acquired immunodeficiency syndrome	0.00139	0.011	CbGeAlD
Pentoxifylline—ADORA2A—brain—acquired immunodeficiency syndrome	0.00135	0.0107	CbGeAlD
Pentoxifylline—PDE4B—bone marrow—acquired immunodeficiency syndrome	0.00135	0.0107	CbGeAlD
Pentoxifylline—PDE4B—spinal cord—acquired immunodeficiency syndrome	0.00134	0.0106	CbGeAlD
Pentoxifylline—PDE4B—vagina—acquired immunodeficiency syndrome	0.00129	0.0102	CbGeAlD
Pentoxifylline—PDE5A—brain—acquired immunodeficiency syndrome	0.00123	0.00976	CbGeAlD
Pentoxifylline—PDE4B—lung—acquired immunodeficiency syndrome	0.00122	0.00967	CbGeAlD
Pentoxifylline—PDE5A—lymph node—acquired immunodeficiency syndrome	0.00119	0.00943	CbGeAlD
Pentoxifylline—ADORA1—brain—acquired immunodeficiency syndrome	0.00117	0.00925	CbGeAlD
Pentoxifylline—PDE4B—nervous system—acquired immunodeficiency syndrome	0.00113	0.00895	CbGeAlD
Pentoxifylline—ADORA1—lymph node—acquired immunodeficiency syndrome	0.00113	0.00894	CbGeAlD
Pentoxifylline—PDE4B—central nervous system—acquired immunodeficiency syndrome	0.00109	0.00862	CbGeAlD
Pentoxifylline—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000897	0.00711	CbGeAlD
Pentoxifylline—PDE4B—brain—acquired immunodeficiency syndrome	0.000864	0.00684	CbGeAlD
Pentoxifylline—CYP1A2—blood—acquired immunodeficiency syndrome	0.000855	0.00677	CbGeAlD
Pentoxifylline—PDE4B—lymph node—acquired immunodeficiency syndrome	0.000834	0.00661	CbGeAlD
Pentoxifylline—CYP1A2—lung—acquired immunodeficiency syndrome	0.000749	0.00594	CbGeAlD
Pentoxifylline—NT5E—Differentiation Pathway—IL6—acquired immunodeficiency syndrome	0.000707	0.0129	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000707	0.0129	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000697	0.0128	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000652	0.0119	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00059	0.0108	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000555	0.0101	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000538	0.00984	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—TAT—acquired immunodeficiency syndrome	0.000524	0.00958	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000502	0.00917	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000497	0.00909	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000449	0.00822	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000445	0.00815	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000428	0.00783	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000425	0.00778	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	0.000422	0.00773	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000422	0.00773	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000421	0.0077	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000414	0.00758	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000403	0.00737	CbGpPWpGaD
Pentoxifylline—ADORA2A—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.000402	0.00736	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.0004	0.00732	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00039	0.00713	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000387	0.00708	CbGpPWpGaD
Pentoxifylline—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000386	0.00112	CcSEcCtD
Pentoxifylline—Rash—Didanosine—acquired immunodeficiency syndrome	0.000385	0.00111	CcSEcCtD
Pentoxifylline—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000385	0.00111	CcSEcCtD
Pentoxifylline—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000385	0.00111	CcSEcCtD
Pentoxifylline—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000385	0.00111	CcSEcCtD
Pentoxifylline—Headache—Didanosine—acquired immunodeficiency syndrome	0.000382	0.00111	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000382	0.00699	CbGpPWpGaD
Pentoxifylline—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000382	0.0011	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000382	0.00699	CbGpPWpGaD
Pentoxifylline—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000381	0.0011	CcSEcCtD
Pentoxifylline—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000381	0.0011	CcSEcCtD
Pentoxifylline—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000381	0.0011	CcSEcCtD
Pentoxifylline—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000381	0.0011	CcSEcCtD
Pentoxifylline—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00038	0.0011	CcSEcCtD
Pentoxifylline—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00038	0.0011	CcSEcCtD
Pentoxifylline—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00038	0.0011	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000379	0.0011	CcSEcCtD
Pentoxifylline—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000379	0.0011	CcSEcCtD
Pentoxifylline—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000378	0.00109	CcSEcCtD
Pentoxifylline—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000378	0.00109	CcSEcCtD
Pentoxifylline—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000378	0.00109	CcSEcCtD
Pentoxifylline—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000377	0.00109	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000377	0.00109	CcSEcCtD
Pentoxifylline—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000376	0.00109	CcSEcCtD
Pentoxifylline—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000376	0.00109	CcSEcCtD
Pentoxifylline—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000376	0.00109	CcSEcCtD
Pentoxifylline—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000375	0.00108	CcSEcCtD
Pentoxifylline—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000375	0.00108	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000374	0.00108	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000374	0.00108	CcSEcCtD
Pentoxifylline—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000374	0.00108	CcSEcCtD
Pentoxifylline—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000374	0.00108	CcSEcCtD
Pentoxifylline—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000372	0.00108	CcSEcCtD
Pentoxifylline—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000372	0.00108	CcSEcCtD
Pentoxifylline—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000372	0.00108	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000371	0.00107	CcSEcCtD
Pentoxifylline—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000369	0.00107	CcSEcCtD
Pentoxifylline—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000369	0.00107	CcSEcCtD
Pentoxifylline—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000369	0.00107	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000369	0.00107	CcSEcCtD
Pentoxifylline—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000368	0.00107	CcSEcCtD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000366	0.0067	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000366	0.0067	CbGpPWpGaD
Pentoxifylline—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000366	0.00106	CcSEcCtD
Pentoxifylline—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000366	0.00106	CcSEcCtD
Pentoxifylline—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000366	0.00106	CcSEcCtD
Pentoxifylline—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000366	0.00106	CcSEcCtD
Pentoxifylline—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000365	0.00106	CcSEcCtD
Pentoxifylline—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000365	0.00105	CcSEcCtD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000364	0.00667	CbGpPWpGaD
Pentoxifylline—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.00105	CcSEcCtD
Pentoxifylline—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.00105	CcSEcCtD
Pentoxifylline—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000364	0.00105	CcSEcCtD
Pentoxifylline—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000363	0.00105	CcSEcCtD
Pentoxifylline—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000363	0.00105	CcSEcCtD
Pentoxifylline—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000363	0.00105	CcSEcCtD
Pentoxifylline—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000362	0.00105	CcSEcCtD
Pentoxifylline—ADORA1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000362	0.00662	CbGpPWpGaD
Pentoxifylline—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000361	0.00104	CcSEcCtD
Pentoxifylline—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000361	0.00104	CcSEcCtD
Pentoxifylline—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000361	0.00104	CcSEcCtD
Pentoxifylline—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00036	0.00104	CcSEcCtD
Pentoxifylline—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00036	0.00104	CcSEcCtD
Pentoxifylline—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.00036	0.00104	CcSEcCtD
Pentoxifylline—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000358	0.00104	CcSEcCtD
Pentoxifylline—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000358	0.00104	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000358	0.00654	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000357	0.00103	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000357	0.00103	CcSEcCtD
Pentoxifylline—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000356	0.00103	CcSEcCtD
Pentoxifylline—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000355	0.00103	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000353	0.00647	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000353	0.00102	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000353	0.00102	CcSEcCtD
Pentoxifylline—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000352	0.00102	CcSEcCtD
Pentoxifylline—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000352	0.00102	CcSEcCtD
Pentoxifylline—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000352	0.00102	CcSEcCtD
Pentoxifylline—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000352	0.00102	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000351	0.00101	CcSEcCtD
Pentoxifylline—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00035	0.00101	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00035	0.00101	CcSEcCtD
Pentoxifylline—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00035	0.00101	CcSEcCtD
Pentoxifylline—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00035	0.00101	CcSEcCtD
Pentoxifylline—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000349	0.00101	CcSEcCtD
Pentoxifylline—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000349	0.00101	CcSEcCtD
Pentoxifylline—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000348	0.00101	CcSEcCtD
Pentoxifylline—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000348	0.00101	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000346	0.001	CcSEcCtD
Pentoxifylline—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000346	0.001	CcSEcCtD
Pentoxifylline—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000346	0.001	CcSEcCtD
Pentoxifylline—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000346	0.001	CcSEcCtD
Pentoxifylline—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000345	0.000999	CcSEcCtD
Pentoxifylline—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000345	0.000999	CcSEcCtD
Pentoxifylline—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.000997	CcSEcCtD
Pentoxifylline—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000344	0.000996	CcSEcCtD
Pentoxifylline—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000344	0.000995	CcSEcCtD
Pentoxifylline—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000343	0.000992	CcSEcCtD
Pentoxifylline—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000343	0.000992	CcSEcCtD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000343	0.00627	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000343	0.00627	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000343	0.00627	CbGpPWpGaD
Pentoxifylline—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000342	0.000991	CcSEcCtD
Pentoxifylline—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000342	0.000989	CcSEcCtD
Pentoxifylline—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000341	0.000988	CcSEcCtD
Pentoxifylline—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000341	0.000986	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000341	0.000986	CcSEcCtD
Pentoxifylline—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00034	0.000985	CcSEcCtD
Pentoxifylline—ADORA1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00034	0.00622	CbGpPWpGaD
Pentoxifylline—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000339	0.000981	CcSEcCtD
Pentoxifylline—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000339	0.000981	CcSEcCtD
Pentoxifylline—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000339	0.00098	CcSEcCtD
Pentoxifylline—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000339	0.00098	CcSEcCtD
Pentoxifylline—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000338	0.000978	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000338	0.000976	CcSEcCtD
Pentoxifylline—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000337	0.000975	CcSEcCtD
Pentoxifylline—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000337	0.000974	CcSEcCtD
Pentoxifylline—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000336	0.000971	CcSEcCtD
Pentoxifylline—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000335	0.00097	CcSEcCtD
Pentoxifylline—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000335	0.000969	CcSEcCtD
Pentoxifylline—PDE5A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000335	0.00613	CbGpPWpGaD
Pentoxifylline—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000335	0.000969	CcSEcCtD
Pentoxifylline—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000335	0.000968	CcSEcCtD
Pentoxifylline—Rash—Stavudine—acquired immunodeficiency syndrome	0.000334	0.000967	CcSEcCtD
Pentoxifylline—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000334	0.000966	CcSEcCtD
Pentoxifylline—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000334	0.000965	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000333	0.000964	CcSEcCtD
Pentoxifylline—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000333	0.000963	CcSEcCtD
Pentoxifylline—Headache—Stavudine—acquired immunodeficiency syndrome	0.000332	0.000961	CcSEcCtD
Pentoxifylline—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000332	0.00096	CcSEcCtD
Pentoxifylline—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000332	0.000959	CcSEcCtD
Pentoxifylline—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000331	0.000958	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000331	0.000958	CcSEcCtD
Pentoxifylline—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000331	0.000956	CcSEcCtD
Pentoxifylline—Rash—Abacavir—acquired immunodeficiency syndrome	0.000329	0.000952	CcSEcCtD
Pentoxifylline—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000329	0.000952	CcSEcCtD
Pentoxifylline—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000329	0.000951	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000329	0.000951	CcSEcCtD
Pentoxifylline—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000329	0.000951	CcSEcCtD
Pentoxifylline—Headache—Abacavir—acquired immunodeficiency syndrome	0.000327	0.000946	CcSEcCtD
Pentoxifylline—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.000945	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.000944	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000326	0.00596	CbGpPWpGaD
Pentoxifylline—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000326	0.000943	CcSEcCtD
Pentoxifylline—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000326	0.000943	CcSEcCtD
Pentoxifylline—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000324	0.000937	CcSEcCtD
Pentoxifylline—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000324	0.000936	CcSEcCtD
Pentoxifylline—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000322	0.000932	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000322	0.000931	CcSEcCtD
Pentoxifylline—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000322	0.00093	CcSEcCtD
Pentoxifylline—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.000926	CcSEcCtD
Pentoxifylline—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.000926	CcSEcCtD
Pentoxifylline—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000319	0.000924	CcSEcCtD
Pentoxifylline—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000319	0.000924	CcSEcCtD
Pentoxifylline—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000319	0.000923	CcSEcCtD
Pentoxifylline—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000318	0.000921	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000318	0.00092	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000317	0.000916	CcSEcCtD
Pentoxifylline—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000316	0.000914	CcSEcCtD
Pentoxifylline—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000316	0.000913	CcSEcCtD
Pentoxifylline—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000315	0.000912	CcSEcCtD
Pentoxifylline—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000315	0.000912	CcSEcCtD
Pentoxifylline—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000315	0.000911	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000314	0.000909	CcSEcCtD
Pentoxifylline—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000313	0.000907	CcSEcCtD
Pentoxifylline—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.000902	CcSEcCtD
Pentoxifylline—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000311	0.000901	CcSEcCtD
Pentoxifylline—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00031	0.000897	CcSEcCtD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00031	0.00567	CbGpPWpGaD
Pentoxifylline—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000308	0.00089	CcSEcCtD
Pentoxifylline—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000307	0.000889	CcSEcCtD
Pentoxifylline—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000307	0.000889	CcSEcCtD
Pentoxifylline—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000307	0.000889	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000307	0.00561	CbGpPWpGaD
Pentoxifylline—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000306	0.000887	CcSEcCtD
Pentoxifylline—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000306	0.000886	CcSEcCtD
Pentoxifylline—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.000886	CcSEcCtD
Pentoxifylline—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.000886	CcSEcCtD
Pentoxifylline—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000305	0.000881	CcSEcCtD
Pentoxifylline—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000303	0.000878	CcSEcCtD
Pentoxifylline—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000303	0.000877	CcSEcCtD
Pentoxifylline—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.0003	0.000867	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.0003	0.000867	CcSEcCtD
Pentoxifylline—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000298	0.000863	CcSEcCtD
Pentoxifylline—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000297	0.00086	CcSEcCtD
Pentoxifylline—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000295	0.000854	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000295	0.00539	CbGpPWpGaD
Pentoxifylline—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.000853	CcSEcCtD
Pentoxifylline—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000293	0.000848	CcSEcCtD
Pentoxifylline—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000293	0.000848	CcSEcCtD
Pentoxifylline—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000293	0.000847	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000293	0.000847	CcSEcCtD
Pentoxifylline—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000292	0.000846	CcSEcCtD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000291	0.00533	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000291	0.00533	CbGpPWpGaD
Pentoxifylline—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00029	0.00084	CcSEcCtD
Pentoxifylline—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00029	0.00084	CcSEcCtD
Pentoxifylline—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00029	0.00084	CcSEcCtD
Pentoxifylline—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000289	0.000837	CcSEcCtD
Pentoxifylline—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000289	0.000835	CcSEcCtD
Pentoxifylline—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000286	0.000828	CcSEcCtD
Pentoxifylline—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000286	0.000827	CcSEcCtD
Pentoxifylline—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000285	0.000825	CcSEcCtD
Pentoxifylline—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000285	0.000823	CcSEcCtD
Pentoxifylline—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000284	0.000822	CcSEcCtD
Pentoxifylline—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000283	0.00082	CcSEcCtD
Pentoxifylline—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000819	CcSEcCtD
Pentoxifylline—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000819	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000282	0.000815	CcSEcCtD
Pentoxifylline—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000281	0.000814	CcSEcCtD
Pentoxifylline—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000279	0.00511	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000279	0.0051	CbGpPWpGaD
Pentoxifylline—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000278	0.000804	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000278	0.00508	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000277	0.000801	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000276	0.00505	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000274	0.00501	CbGpPWpGaD
Pentoxifylline—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000274	0.000793	CcSEcCtD
Pentoxifylline—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000274	0.000792	CcSEcCtD
Pentoxifylline—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000274	0.000792	CcSEcCtD
Pentoxifylline—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.000788	CcSEcCtD
Pentoxifylline—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.000788	CcSEcCtD
Pentoxifylline—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000272	0.000788	CcSEcCtD
Pentoxifylline—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.000784	CcSEcCtD
Pentoxifylline—Rash—Indinavir—acquired immunodeficiency syndrome	0.00027	0.000781	CcSEcCtD
Pentoxifylline—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00027	0.000781	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000269	0.000778	CcSEcCtD
Pentoxifylline—Headache—Indinavir—acquired immunodeficiency syndrome	0.000268	0.000776	CcSEcCtD
Pentoxifylline—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000268	0.000774	CcSEcCtD
Pentoxifylline—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000265	0.000767	CcSEcCtD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000265	0.00484	CbGpPWpGaD
Pentoxifylline—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000264	0.000763	CcSEcCtD
Pentoxifylline—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000263	0.0048	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000262	0.00479	CbGpPWpGaD
Pentoxifylline—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000756	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000261	0.00477	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000261	0.00477	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000261	0.00477	CbGpPWpGaD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000261	0.00477	CbGpPWpGaD
Pentoxifylline—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000752	CcSEcCtD
Pentoxifylline—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000752	CcSEcCtD
Pentoxifylline—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.000745	CcSEcCtD
Pentoxifylline—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000257	0.000743	CcSEcCtD
Pentoxifylline—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000256	0.000741	CcSEcCtD
Pentoxifylline—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000255	0.000738	CcSEcCtD
Pentoxifylline—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000255	0.000738	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000255	0.00466	CbGpPWpGaD
Pentoxifylline—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000254	0.000736	CcSEcCtD
Pentoxifylline—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000254	0.000735	CcSEcCtD
Pentoxifylline—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000254	0.000734	CcSEcCtD
Pentoxifylline—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000733	CcSEcCtD
Pentoxifylline—ADORA1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000251	0.00459	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000249	0.00455	CbGpPWpGaD
Pentoxifylline—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000247	0.000715	CcSEcCtD
Pentoxifylline—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.000712	CcSEcCtD
Pentoxifylline—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.000709	CcSEcCtD
Pentoxifylline—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000244	0.000706	CcSEcCtD
Pentoxifylline—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000244	0.000706	CcSEcCtD
Pentoxifylline—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.000706	CcSEcCtD
Pentoxifylline—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000243	0.000702	CcSEcCtD
Pentoxifylline—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000242	0.000701	CcSEcCtD
Pentoxifylline—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00024	0.000696	CcSEcCtD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000239	0.00438	CbGpPWpGaD
Pentoxifylline—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000237	0.000685	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000236	0.00432	CbGpPWpGaD
Pentoxifylline—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000236	0.000683	CcSEcCtD
Pentoxifylline—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000682	CcSEcCtD
Pentoxifylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000235	0.0043	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000233	0.00426	CbGpPWpGaD
Pentoxifylline—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000673	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000231	0.00423	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000231	0.00422	CbGpPWpGaD
Pentoxifylline—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00023	0.000666	CcSEcCtD
Pentoxifylline—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000228	0.000659	CcSEcCtD
Pentoxifylline—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000228	0.000659	CcSEcCtD
Pentoxifylline—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.000653	CcSEcCtD
Pentoxifylline—PDE4A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000226	0.00413	CbGpPWpGaD
Pentoxifylline—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.000653	CcSEcCtD
Pentoxifylline—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000651	CcSEcCtD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000225	0.00411	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000225	0.00411	CbGpPWpGaD
Pentoxifylline—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.000649	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000222	0.00406	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000222	0.00406	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000222	0.00405	CbGpPWpGaD
Pentoxifylline—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000634	CcSEcCtD
Pentoxifylline—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.000629	CcSEcCtD
Pentoxifylline—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000629	CcSEcCtD
Pentoxifylline—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000628	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000217	0.00396	CbGpPWpGaD
Pentoxifylline—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000216	0.000625	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000214	0.00392	CbGpPWpGaD
Pentoxifylline—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.000615	CcSEcCtD
Pentoxifylline—ADORA1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000211	0.00387	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000209	0.00383	CbGpPWpGaD
Pentoxifylline—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.000605	CcSEcCtD
Pentoxifylline—PDE4B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000209	0.00382	CbGpPWpGaD
Pentoxifylline—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.0006	CcSEcCtD
Pentoxifylline—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.000599	CcSEcCtD
Pentoxifylline—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000206	0.000596	CcSEcCtD
Pentoxifylline—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000592	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000201	0.00368	CbGpPWpGaD
Pentoxifylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.0002	0.00365	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000198	0.00363	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000196	0.00359	CbGpPWpGaD
Pentoxifylline—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000565	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000194	0.00354	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000182	0.00333	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00018	0.00329	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000179	0.00327	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000171	0.00313	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000171	0.00313	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000171	0.00313	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000171	0.00312	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000169	0.00309	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000167	0.00306	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000163	0.00298	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000157	0.00288	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000157	0.00287	CbGpPWpGaD
Pentoxifylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000154	0.00282	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000152	0.00278	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000151	0.00277	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000151	0.00275	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000151	0.00275	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000147	0.0027	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000147	0.0027	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000143	0.00262	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000142	0.00261	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000142	0.0026	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—IL2—acquired immunodeficiency syndrome	0.000138	0.00253	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000137	0.0025	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000137	0.0025	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000136	0.00249	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000134	0.00245	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000134	0.00245	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000134	0.00245	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000134	0.00245	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000134	0.00245	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000133	0.00244	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000132	0.00242	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000132	0.00241	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00013	0.00238	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000129	0.00237	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000129	0.00236	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000128	0.00234	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000128	0.00234	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000127	0.00231	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000127	0.00231	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000125	0.00229	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000125	0.00229	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000124	0.00227	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000124	0.00227	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000124	0.00226	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000122	0.00222	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000122	0.00222	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000121	0.00221	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00012	0.00219	CbGpPWpGaD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	0.000118	0.00215	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000117	0.00215	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000116	0.00212	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000115	0.0021	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000114	0.00209	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00208	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000114	0.00208	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000113	0.00206	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000113	0.00206	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000112	0.00205	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00011	0.00202	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000103	0.00189	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000103	0.00188	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000102	0.00186	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000102	0.00186	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000101	0.00185	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.0001	0.00184	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.0001	0.00184	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.89e-05	0.00181	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.89e-05	0.00181	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.68e-05	0.00177	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.68e-05	0.00177	CbGpPWpGaD
Pentoxifylline—ADORA1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	9.66e-05	0.00177	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.54e-05	0.00174	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.42e-05	0.00172	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.4e-05	0.00172	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.35e-05	0.00171	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.3e-05	0.0017	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.28e-05	0.0017	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.25e-05	0.00169	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.22e-05	0.00169	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.18e-05	0.00168	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.18e-05	0.00168	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—ALB—acquired immunodeficiency syndrome	9.14e-05	0.00167	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.11e-05	0.00167	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.94e-05	0.00164	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.79e-05	0.00161	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.79e-05	0.00161	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.66e-05	0.00158	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.59e-05	0.00157	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.56e-05	0.00157	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.53e-05	0.00156	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.49e-05	0.00155	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.45e-05	0.00155	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.43e-05	0.00154	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.41e-05	0.00154	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	8.35e-05	0.00153	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	8.35e-05	0.00153	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.33e-05	0.00152	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.91e-05	0.00145	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.91e-05	0.00145	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.91e-05	0.00145	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.82e-05	0.00143	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.8e-05	0.00143	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.71e-05	0.00141	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.64e-05	0.0014	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	7.46e-05	0.00136	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.36e-05	0.00135	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	7.32e-05	0.00134	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.25e-05	0.00133	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.18e-05	0.00131	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.18e-05	0.00131	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.15e-05	0.00131	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.07e-05	0.00129	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.73e-05	0.00123	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.73e-05	0.00123	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.69e-05	0.00122	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.65e-05	0.00122	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.65e-05	0.00122	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.63e-05	0.00121	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.59e-05	0.0012	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.11e-05	0.00112	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.02e-05	0.0011	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.02e-05	0.0011	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.93e-05	0.00108	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.84e-05	0.00107	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—IL6—acquired immunodeficiency syndrome	5.63e-05	0.00103	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.52e-05	0.00101	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.46e-05	0.000999	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.42e-05	0.000992	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.38e-05	0.000985	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.3e-05	0.00097	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.3e-05	0.00097	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.19e-05	0.00095	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.19e-05	0.00095	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.12e-05	0.000936	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.06e-05	0.000925	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.04e-05	0.000922	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.98e-05	0.000911	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.96e-05	0.000908	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.92e-05	0.0009	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.91e-05	0.000897	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	4.83e-05	0.000883	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.81e-05	0.000881	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.61e-05	0.000843	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.55e-05	0.000833	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.51e-05	0.000825	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.46e-05	0.000815	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	4.1e-05	0.000751	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.95e-05	0.000723	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.89e-05	0.000712	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.83e-05	0.000701	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.56e-05	0.000651	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.48e-05	0.000637	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.13e-05	0.000573	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.12e-05	0.00057	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.84e-05	0.00052	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.83e-05	0.000518	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.66e-05	0.000487	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.65e-05	0.000485	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.63e-05	0.000481	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.62e-05	0.000479	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.06e-05	0.000376	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.05e-05	0.000374	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.89e-05	0.000346	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.84e-05	0.000337	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.67e-05	0.000306	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.57e-05	0.000286	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.55e-05	0.000283	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000221	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	8.42e-06	0.000154	CbGpPWpGaD
